ArticlePest management science2026
Toxicity of a novel acaricide, bisulflufen, to the two-spotted spider mite Tetranychus urticae.
Article in Pest management science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe two-spotted spider mite (TSSM), Tetranychus urticae, is a major global agricultural pest that has developed resistance to nearly all acaricides used for its control. This study evaluated the toxicity of bisulflufen, a novel phenyl trifluoroethyl thioether acaricide, against the TSSM.
resultsBisulflufen exhibited high toxicity across all developmental stages of the TSSM, with peak activity observed at 72 h post-application compared with 24 and 48 h. In a laboratory-maintained susceptible strain, the median lethal concentration (LC₅₀) values of bisulflufen at 48 h were 9.61 mg L
conclusionThe baseline susceptibility of TSSM female adults to bisulflufen, established using a laboratory susceptible population, yielded an LC₅₀ of 9.61 mg L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.